glp 1 blindness study GLP-1 Receptor Agonists and vision risk Taking a GLP-1 medication? In

A window into the Ebola outbreak Weve been following the Ebola outbreak in the Democratic Republic of the Congo , where just a few days after our last check-in, the World Health Organization declared that responders discharged a (potentially) final patient

Post-market reportswhich may overestimate side effectshave noted renal impairment upon initiation and dose escalation of GLP-1s, possibly due to dehydration from nausea and vomiting [115]

Brello prescribes these medications only after thorough evaluation

Main exclusion criteria included recent gastrointestinal discomfort (e.g., abdominal pain or diarrhea) within the previous month, recent use of antibiotics, use of probiotics or prebiotics within the previous month, and advanced chronic kidney disease or other metabolic disorders (thyroid dysfunction, Cushing syndrome, acromegaly, and pheochromocytoma)

JAMA Cardiology

Clinical trials of GLP-1RAs have primarily focused on patients with obesity or overweight, yet the effectiveness in the cardiovascular protection appears independent of baseline BMI range (265)